Patents by Inventor Adrien Kissenpfennig

Adrien Kissenpfennig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF FKBP-L POLYPEPTIDES AND NUCLEIC ACIDS FOR THE TREATMENT OF OBESITY
    Publication number: 20220347264
    Abstract: The inventors have determined that increasing the expression level or activity of FKBP-L polypeptide in a subject, which can be provided by expression of nucleic acids encoding FKBP-L or by providing FKBP-L polypeptides to a subject is advantageous for use in the treatment of obesity and obesity-related disorders. In particular increased expression or activity of FKBP-L polypeptide in a subject may be used to treat excessive weight gain (which can be characterised as obesity), glucose intolerance, diabetes and metabolic syndrome, which are closely linked to obesity and insulin resistance. FKBP-L can also be used as a biomarker for obesity and obesity-related disorders.
    Type: Application
    Filed: May 31, 2022
    Publication date: November 3, 2022
    Inventors: Tracy ROBSON, David GRIEVE, Amy SHORT, Adrien KISSENPFENNIG, Marie MIGAUD, Rachel BENNETT, Anita YAKKUNDI, Helen MCCARTHY
  • Use of FKBP-L polypeptides and nucleic acids for the treatment of obesity
    Patent number: 11376308
    Abstract: The inventors have determined that increasing the expression level or activity of FKBP-L polypeptide in a subject, which can be provided by expression of nucleic acids encoding FKBP-L or by providing FKBP-L polypeptides to a subject is advantageous for use in the treatment of obesity and obesity-related disorders. In particular increased expression or activity of FKBP-L polypeptide in a subject may be used to treat excessive weight gain (which can be characterised as obesity), glucose intolerance, diabetes and metabolic syndrome, which are closely linked to obesity and insulin resistance. FKBP-L can also be used as a biomarker for obesity and obesity-related disorders.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: July 5, 2022
    Assignee: Royal College of Surgeons in Ireland
    Inventors: Tracy Robson, David Grieve, Amy Short, Adrien Kissenpfennig, Marie Migaud, Rachel Bennett, Anita Yakkundi, Helen McCarthy